Plasminogen activator inhibitor-1 levels as an indicator of severity and mortality for COVID-19.

IF 0.9 Q3 MEDICINE, GENERAL & INTERNAL
Omer Faruk Baycan, Hasan Ali Barman, Furkan Bolen, Adem Atici, Hayriye Erman, Rabia Korkmaz, Muhittin Calim, Basak Atalay, Gonul Aciksari, Mustafa Baki Cekmen, Haluk Vahaboglu, Mustafa Caliskan
{"title":"Plasminogen activator inhibitor-1 levels as an indicator of severity and mortality for COVID-19.","authors":"Omer Faruk Baycan,&nbsp;Hasan Ali Barman,&nbsp;Furkan Bolen,&nbsp;Adem Atici,&nbsp;Hayriye Erman,&nbsp;Rabia Korkmaz,&nbsp;Muhittin Calim,&nbsp;Basak Atalay,&nbsp;Gonul Aciksari,&nbsp;Mustafa Baki Cekmen,&nbsp;Haluk Vahaboglu,&nbsp;Mustafa Caliskan","doi":"10.14744/nci.2022.09076","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Coronavirus disease-19 (COVID-19) is a multisystemic disease that can cause severe illness and mortality by exacerbating symptoms such as thrombosis, fibrinolysis, and inflammation. Plasminogen activator inhibitor-1 (PAI-1) plays an important role in regulating fibrinolysis and may cause thrombotic events to develop. The goal of this study is to examine the relationship between PAI-1 levels and disease severity and mortality in relation to COVID-19.</p><p><strong>Methods: </strong>A total of 71 hospitalized patients were diagnosed with COVID-19 using real time-polymerase chain reaction tests. Each patient underwent chest computerized tomography (CT). Data from an additional 20 volunteers without COVID-19 were included in this single-center study. Each patient's PAI-1 data were collected at admission, and the CT severity score (CT-SS) was then calculated for each patient.</p><p><strong>Results: </strong>The patients were categorized into the control group (n=20), the survivor group (n=47), and the non-survivor group (n=24). In the non-survivor group, the mean age was 75.3±13.8, which is higher than in the survivor group (61.7±16.9) and in the control group (59.5±11.2), (p=0.001). When the PAI-1 levels were compared between each group, the non-survivor group showed the highest levels, followed by the survivor group and then the control group (p<0.001). Logistic regression analysis revealed that age, PAI-1, and disease severity independently predicted COVID-19 mortality rates. In this study, it was observed that PAI-1 levels with >10.2 ng/mL had 83% sensitivity and an 83% specificity rate when used to predict mortality after COVID-19. Then, patients were divided into severe (n=33) and non-severe (n=38) groups according to disease severity levels. The PAI-1 levels found were higher in the severe group (p<0.001) than in the non-severe group. In the regression analysis that followed, high sensitive troponin I and PAI-1 were found to indicate disease severity levels. The CT-SS was estimated as significantly higher in the non-survivor group compared to the survivor group (p<0.001). When comparing CT-SS between the severe group and the non-severe group, this was significantly higher in the severe group (p<0.001). In addition, a strong statistically significant positive correlation was found between CT-SS and PAI-1 levels (r: 0.838, p<0.001).</p><p><strong>Conclusion: </strong>Anticipating poor clinical outcomes in relation to COVID-19 is crucial. This study showed that PAI-1 levels could independently predict disease severity and mortality rates for patients with COVID-19.</p>","PeriodicalId":19164,"journal":{"name":"Northern Clinics of Istanbul","volume":"10 1","pages":"1-9"},"PeriodicalIF":0.9000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/47/3b/NCI-10-001.PMC9996651.pdf","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Northern Clinics of Istanbul","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14744/nci.2022.09076","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 2

Abstract

Objective: Coronavirus disease-19 (COVID-19) is a multisystemic disease that can cause severe illness and mortality by exacerbating symptoms such as thrombosis, fibrinolysis, and inflammation. Plasminogen activator inhibitor-1 (PAI-1) plays an important role in regulating fibrinolysis and may cause thrombotic events to develop. The goal of this study is to examine the relationship between PAI-1 levels and disease severity and mortality in relation to COVID-19.

Methods: A total of 71 hospitalized patients were diagnosed with COVID-19 using real time-polymerase chain reaction tests. Each patient underwent chest computerized tomography (CT). Data from an additional 20 volunteers without COVID-19 were included in this single-center study. Each patient's PAI-1 data were collected at admission, and the CT severity score (CT-SS) was then calculated for each patient.

Results: The patients were categorized into the control group (n=20), the survivor group (n=47), and the non-survivor group (n=24). In the non-survivor group, the mean age was 75.3±13.8, which is higher than in the survivor group (61.7±16.9) and in the control group (59.5±11.2), (p=0.001). When the PAI-1 levels were compared between each group, the non-survivor group showed the highest levels, followed by the survivor group and then the control group (p<0.001). Logistic regression analysis revealed that age, PAI-1, and disease severity independently predicted COVID-19 mortality rates. In this study, it was observed that PAI-1 levels with >10.2 ng/mL had 83% sensitivity and an 83% specificity rate when used to predict mortality after COVID-19. Then, patients were divided into severe (n=33) and non-severe (n=38) groups according to disease severity levels. The PAI-1 levels found were higher in the severe group (p<0.001) than in the non-severe group. In the regression analysis that followed, high sensitive troponin I and PAI-1 were found to indicate disease severity levels. The CT-SS was estimated as significantly higher in the non-survivor group compared to the survivor group (p<0.001). When comparing CT-SS between the severe group and the non-severe group, this was significantly higher in the severe group (p<0.001). In addition, a strong statistically significant positive correlation was found between CT-SS and PAI-1 levels (r: 0.838, p<0.001).

Conclusion: Anticipating poor clinical outcomes in relation to COVID-19 is crucial. This study showed that PAI-1 levels could independently predict disease severity and mortality rates for patients with COVID-19.

Abstract Image

Abstract Image

纤溶酶原激活物抑制剂-1水平作为COVID-19严重程度和死亡率的指标
目的:冠状病毒病-19 (COVID-19)是一种多系统疾病,可通过加重血栓形成、纤维蛋白溶解和炎症等症状导致严重疾病和死亡。纤溶酶原激活物抑制剂-1 (PAI-1)在调节纤维蛋白溶解中起重要作用,并可能导致血栓事件的发生。本研究的目的是研究PAI-1水平与COVID-19相关的疾病严重程度和死亡率之间的关系。方法:采用实时聚合酶链反应检测方法对71例新冠肺炎住院患者进行诊断。每位患者均行胸部计算机断层扫描(CT)。另外20名没有COVID-19的志愿者的数据被纳入了这项单中心研究。入院时收集每位患者的PAI-1数据,然后计算每位患者的CT严重程度评分(CT- ss)。结果:患者分为对照组(n=20)、生存组(n=47)和非生存组(n=24)。非存活组平均年龄为75.3±13.8岁,高于存活组(61.7±16.9)岁和对照组(59.5±11.2)岁,差异有统计学意义(p=0.001)。当比较各组之间PAI-1水平时,非幸存者组的PAI-1水平最高,其次是幸存者组,然后是对照组(p10.2 ng/mL用于预测COVID-19后死亡率的敏感性为83%,特异性为83%)。然后根据病情严重程度将患者分为重症组(n=33)和非重症组(n=38)。结论:预测与COVID-19相关的不良临床结果至关重要。本研究表明PAI-1水平可以独立预测COVID-19患者的疾病严重程度和死亡率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Northern Clinics of Istanbul
Northern Clinics of Istanbul MEDICINE, GENERAL & INTERNAL-
CiteScore
0.40
自引率
0.00%
发文量
48
审稿时长
10 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信